Research Analysts Issue Forecasts for TG Therapeutics Inc’s Q2 2019 Earnings (NASDAQ:TGTX)

TG Therapeutics Inc (NASDAQ:TGTX) – Research analysts at B. Riley issued their Q2 2019 EPS estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, June 11th. B. Riley analyst H. Polishetty forecasts that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for TG Therapeutics’ Q3 2019 earnings at ($0.34) EPS, Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.41) EPS, FY2020 earnings at ($1.26) EPS, FY2021 earnings at ($0.96) EPS, FY2022 earnings at ($0.63) EPS and FY2023 earnings at $0.24 EPS.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 price target on shares of TG Therapeutics in a research report on Monday, May 13th. Zacks Investment Research lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. BidaskClub lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of TG Therapeutics in a research report on Friday, April 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and an average price target of $14.07.

TGTX opened at $7.26 on Friday. TG Therapeutics has a 12-month low of $3.32 and a 12-month high of $14.65. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.72 and a quick ratio of 1.72.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million.

Several large investors have recently bought and sold shares of the company. venBio Select Advisor LLC increased its holdings in shares of TG Therapeutics by 13.1% during the 4th quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after purchasing an additional 549,969 shares in the last quarter. BlackRock Inc. increased its holdings in shares of TG Therapeutics by 2.2% during the 4th quarter. BlackRock Inc. now owns 4,519,331 shares of the biopharmaceutical company’s stock valued at $18,529,000 after purchasing an additional 98,479 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of TG Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock valued at $17,125,000 after purchasing an additional 268,483 shares in the last quarter. Great Point Partners LLC increased its holdings in shares of TG Therapeutics by 53.8% during the 4th quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $12,300,000 after purchasing an additional 1,050,000 shares in the last quarter. Finally, Opaleye Management Inc. increased its holdings in shares of TG Therapeutics by 148.4% during the 1st quarter. Opaleye Management Inc. now owns 1,366,062 shares of the biopharmaceutical company’s stock valued at $10,983,000 after purchasing an additional 816,062 shares in the last quarter. 54.60% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Story: Why are percentage decliners important?

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit